In August 2023, Johnson & Johnson completed the spin-off of its consumer health business into a separate publicly traded company called Kenvue, allowing J&J to focus more intensely on its pharmaceutical and medical technology segments. This move was aimed at streamlining operations and enhancing shareholder value, with Kenvue now handling iconic brands like Tylenol and Band-Aid. Earlier in 2023, the company faced significant legal challenges with a proposed $8.9 billion settlement for talc-related lawsuits, which allege that its baby powder caused cancer, though J&J maintains the product's safety. In January 2024, J&J acquired Ambrx Biopharma for $2 billion to bolster its oncology pipeline, particularly in antibody-drug conjugates for cancer treatment. Additionally, in late 2022, J&J finalized the $16.6 billion acquisition of Abiomed, a leader in heart pump technology, strengthening its cardiovascular medtech portfolio. These developments highlight J&J's strategic pivots amid legal and market pressures.

Johnson & Johnson, founded in 1886 and headquartered in New Brunswick, New Jersey, is a global healthcare leader with a market capitalization exceeding $350 billion as of 2024. The company operates through two main segments: Innovative Medicine (formerly Janssen Pharmaceuticals) and MedTech, focusing on pharmaceuticals, medical devices, and diagnostics. Currently positioned as a top player in the healthcare industry, J&J emphasizes innovation in areas like immunology, oncology, and surgical robotics, with a strong commitment to global health equity. Its credo, established in 1943, prioritizes responsibilities to customers, employees, communities, and shareholders, guiding its ethical framework. J&J's extensive portfolio includes blockbuster drugs like Stelara and Darzalex, alongside medtech innovations such as the Ethicon surgical suite. This positioning makes it an attractive employer for young professionals seeking impactful roles in a stable, mission-driven organization.

Johnson & Johnson's tech department leverages key competitive advantages like its vast data resources from clinical trials and patient interactions, enabling advanced AI applications in drug discovery and personalized medicine. The company invests heavily in digital health platforms, such as the Health Partner app for orthopedic patients and AI-driven tools for supply chain optimization in its medtech division. Its industry, healthcare, is exceptionally well-positioned for innovation due to rapid advancements in biotech and telemedicine, with J&J collaborating on projects like AI for early disease detection. Reputation-wise, J&J is known for strong career development programs, including rotational opportunities in software engineering and product management, often praised in employee reviews. Salaries are competitive, averaging around $120,000 for entry-level software engineers according to industry salary data, though work-life balance can vary by division. Overall, it's viewed as a solid choice for tech careers in a purpose-oriented field.

Johnson & Johnson faces main challenges from ongoing litigation, including opioid crisis settlements and talc lawsuits that have cost billions and damaged public perception. Opportunities lie in expanding its oncology and immunology pipelines, with potential growth from acquisitions like Ambrx and emerging markets in Asia-Pacific. Threats include intense competition from rivals such as Pfizer and Medtronic, who are advancing in similar therapeutic areas and medtech innovations. Regulatory hurdles, like FDA approvals for new drugs, pose limitations, especially with patent expirations on key products like Stelara looming by 2025. Additionally, supply chain disruptions and geopolitical tensions could impact global operations. Despite these, J&J's diversified portfolio provides resilience against market volatility.